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INTRODUCTION 
 
Colorectal cancer is the third most common cancer in the world, and the second most 
common cause of cancer related death. A large body of evidence from epidemiological 
studies and clinical trials in patients with the hereditary colon cancer syndrome, familial 
adenomatosus polyposis coli (FAP), indicates that aspirin and related drugs, known as 
nonsteroideal antiinflammatory drugs (NSAIDs), share the property of inhibiting the 
ciclooxygenase (COX) enzyme, hinder the development of colon cancer and perhaps other 
cancer as well. COX is the rate limiting enzyme for the synthesis of eicosanoids, such as 
prostaglandins, from arachidonic acid. Two Cox isoforms have been identified: COX-1 
constituvely expressed and COX-2, inducible form. COX-1 gene is an housekeeping gene and 
has an important role in protecting the gastroduodenal mucosa. COX-2 gene, an immediate 
early response gene, is rapidly induced in response to tumour promotes, cytokines, and 
growth factors (Du Bois et al. 1994, Di Popolo et al. 2000). COX-2, but not COX-1 
expression was found to be increased in colorectal cancer (Eberhart et al. 1994). Numerous 
studies have shown that the chemopreventive effect of NSAIDs on colon cancer is mediated 
through inhibition of cell growth and induction of apoptosis. For these effects NSAIDs have 
been empolyed as sensiting agents in chemotherapy. 
Aspirin, a widely used non-steroidal anti-inflammatory drug is a non-selective inhibitor of 
cyclo-oxigenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) ( Taketo.1998). High doses of 
salicylates (4 to 10 g per day), including sodium salicylate and aspirin, have been used to treat 
inflammatory conditions such as rheumatic fever and rheumatoid arthritis. There are several 
actions displayed by high doses of aspirin independent from its ability to inhibit 
cyclooxygenases. These includes: i)inhibition of the activation of nuclear factor-kappaB (NF-
kB) by prevention the phosphorylation and degradation of the inhibitory subunit Ik( Yin et 
al. 1998) ; ii) modulation of gene transcription (XU et al. 1999); iii) modulation of several 
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protein kinases and other molecular signaling pathways as well (Pillinger et al. 1998, Dong et 
al. 1997). Several effects have been demostrated in vitro: aspirin treatment inhibits cell 
growth (Ricchi et al. 1997, Redondo et al. 2003) and protects against a variety of toxic stimuli 
such as H2O2, free radicals, hypoxia and chemical toxic (Grilli et al.1996, Mattie et al. 2001). 
In a previous work we have shown that aspirin treatment may affect the proliferation, 
differentiation and apoptosis of the human colon adenocarcinoma Caco-2 cells; in particular, 
we observed that, depending on the doses, aspirin treatment may induce apoptosis and a 
significant DNA synthesis inhibition associated with a modification in the level of the insulin-
like growth factor II (IGF-II) (Ricchi et al, 1997), an autocrine growth factor for this cell line 
(Zarrilli et al, 1994; Zarrilli et al 1996).In addition, we have demonstrated that NS-398, a 
Cox-2 selective inhibitor, also affects Caco-2 DNA synthesis and apoptosis (Di Popolo et al, 
2000). 
Previously we have shown ( Di Popolo et al.; 2000) that COX2 expression and PGE2 
synthesis are up-regulated by an IGFII/IGFI receptor autocrine pathway in CaCo2 colon 
carcinoma cells. Up-regulation of COX2 expression by IGFII is mediated through activation 
of IGFI receptor. The blocked of the PI3kinase, that mediates the proliferative effect of IGFI 
receptor in CaCo2 cells, inhibits IGFII dependent COX2 upregulation and PGE2 synthesis. 
Then, the induction of proliferation and tumor progression of colon cancer cells by the 
IGFII/IGFII receptor pathway may depend on the activation of COX2 related events.We 
analyzed,also, if the inhibition of proliferation and apoptosis by NS398 and by aspirin was 
prostaglandins dependent In these experimental conditions aspirin is able to inhibit cell 
proliferation, to decrease the levels of IGFII, but these effects are not mediated by Cox2 
inhibition, on the contrary the inhibition by NS398 was reverted by exogenous addition of 
PGE2. 
Furthermore, several of the observed effects of NSAIDs in vitro are cell specific and not 
dependent from the inhibition of prostaglandin biosynthesis and probably not relevant for 
prevention in clinical trials (Aas et al. 1995). In fact, a series of studies have evaluated “in 
vitro” the possibility to increase anticancer drugs-induced toxicity and apoptosis through the 
use of older NSAIDs and new coxibs (Sairam et al. 2003 Mattie et al. 2001). But the role of 
NSAIDs as anticancer agent alone and in combination with conventional chemotherapeutic is 
becoming promising also (in vivo) in murine and rat model of cancer (Hundal et al. 2002, 
Vartiainen et al. 2003). In particular, several studies have been focusing on the increase in 
activity and in the changing of toxicity profile by combining a conventional anticancer agent 
with COX-2 inhibitors (Ricchi et al. 2002, Srivastava et al. 1986). Thus during these four 
years of my Phd program the first aim of project has been focused to demostrate: 
 
1)the effect of aspirin on cell cycle and apoptosis alone and in combination with 
conventional anticancer drugs schedules. 
 
2)the molecular  mechanisms  responsible  for the effect of aspirin on cell cycle and 
survival 
 
3)the occurrence of this molecular mechanism and this effect of aspirin also in vivo 
system. 
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RESULTS 
 
The effect of aspirin on cell cycle and apoptosis alone and in combination with 
conventional anticancer drugs schedules 
 
. 
We have previously shown that Caco-2 cells synthesize and secrete IGF-II during their 
replicative phase when this peptide stimulates cell growth by an autocrine loop (Zarrilli et al., 
1994). When cells reach confluence and stop growing, the expression of IGF-II is strongly 
reduced and Caco-2 cells start to differentiate (Pignata et al., 1994; Zarrilli et al., 1994). 
Constitutive IGF-II expression obtained through transfection of Caco-2 cells with rat IGF-II 
cDNA under the control of a viral promoter persistently stimulates cell growth and interferes 
with the enterocyte-like differentiation of this cell line (Zarrilli et al., 1996). To clarifyfurther 
the mechanisms involved in the inhibition of Caco-2 cell replication induced by aspirin, we 
investigated the modifications in IGF-II mRNA expression following drug treatment and 
found that the effect of aspirin on cell growth was associated with a dose-dependent inhibition 
of IGF-II. This finding suggests that a decrease in IGF-II synthesis might be involved in 
aspirin-induce inhibition of cell growth, even though the parallel decrease in IGF-II mRNA 
expression and cell proliferation does not establish cause and effect. Accumulating evidence 
suggest that interference with cell cycle and/or with the intracellular growth factor (receptor)-
activate signal transduction pathways are key modulators of cellular response to 
chemotherapeutic agents (Donaldson et al, 1994; Ciardiello et al, 1996; Tortora et al, 1997; 
Chen et al, 1997; De Luca et al, 1997; Lin et al, 1998). Because aspirin and NS-398 are able 
to inhibit cell growth, I asked whether they might modify sensitivity to anticancer drugs. 
Because cell killing induced by the topoisomerase poisons irinotecan (CPT 11) and etoposide 
(VP-16) is strictly cell cycle dependent (Nitiss and Beck, 1996; Goldwasser et al, 1995) and 
ultimately activates a pathway of programmed cell death, I decided to use these anticancer 
drugs to evaluate this hypothesis. Irinotecan (CPT 11) was selected also because it is one of 
the most active anticancer agent in colon cancer (Rougier et al, 1998). 
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Our previous data indicated that a 24 h aspirin treatment on Caco-2 cells at doses ranging 
from 1 to 10 mM determined a dose-dependent inhibition of DNA synthesis and a significant 
increase in levels of apoptosis (Ricchi et al, 1997). In the present work, I confirmed these 
results on cell growth for a 72 h treatment (data not shown) and evaluated again the effects on 
apoptosis by analysing the percentage of sub-G1 population at flow cytometry. Treatment 
with aspirin for 72 h, caused a dose-dependent increase in apoptosis starting from the 
concentration of 5 mM aspirin; the percentage of apoptotic cells was approximately 6% in 
control cells and 5, 9 and 12% in cells treated with aspirin at 2, 5 and 10 mM, respectively 
(data not shown).The above data suggest that aspirin acts in Caco-2 cells as anticancer agent 
with cytostatic properties and ability to induce apoptosis at high dosages. Therefore I decided 
to select these antiproliferative, apoptotic dosages of drugs to study whether they could 
modify Caco-2 sensitivity to anticancer drug treatments. To determine the effect of anticancer 
drugs on apoptosis, Caco-2 cells were exposed for 48 h at different concentrations of VP-16 
and CPT 11 and DNA ploidy was analysed by flow cytometry. The effects on apoptosis in 
Caco-2 cells are shown in Figure 1. Both Vp-16 and CPT 11 dose-dependently increased the 
levels of apoptosis in Caco-2 cells: Vp-16 increased apoptosis from 8% at 4.25 mM to 20% at 
34 mM (Figure 1A) and CPT 11 increased apoptosis from 9% at 5 mM to 16% at 15 mM 
(Figure 1B).  
 
 
 
 
 
These data suggest that apoptosis may have a role in drug-induced Caco-2 cells cytotoxicity 
especially at high concentrations of the drugs. To evaluate whether aspirin may affect cell 
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killing by topoisomerase drugs, I tested a schedule of administration in which the effects of 
aspirin treatment on Caco-2 cell growth were present at moment of anticancer-drug exposure: 
cells were pre-treated with aspirin for 24 h and subsequently exposed for 48 h to the afore 
mentioned ranges of drugs in the continuous presence of NSAIDs (co-treatment). I evaluated 
the interference of 2 mM aspirin with anticancer drug induced apoptosis through the analysis 
of the sub-diploid DNA peak at flow cytometry. As shown in Figure 1, the levels of apoptosis 
were reduced for each concentration of both anticancer drugs when administered in the 
presence of aspirin compared with single agent treatment. Aspirin-co-treated Caco-2 cells 
were particularly resistant to etoposide-induced apoptosis: in fact the percentage of apoptosis 
in cells co-treated with aspirin and Vp-16 at 8.5 and 17 mM decreased from 14 to 7% and 
from 21 to 9%, respectively. The effect of aspirin on drug induced apoptosis was similar 
when aspirin and anticancer drugs were simultaneously administered (data not shown). These 
results indicate that aspirin-dependent inhibition of proliferation is associated with a reduced 
ability of the drug to  induce apoptosis. To quantify the effects of aspirin co-treatment on Vp-
16- induced apoptosis and to determine whether this effect was present at concentration in 
which aspirin was already apoptotic by itself, I used annexin V-FITC/propidium iodide 
staining assay. In fact this assay allows to clearly distinguish viable cells from those 
undergoing different stages of apoptosis or necrosis. The effect of aspirin at 2 and 5 mM 
concentration on Vp-16-induced toxicity in Caco-2 cells is analysed in Figure 2. 
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Dot plots of green (Annexin V-FITC) vs red (PI) fluorescence showed four separate clusters: 
viable cell (lower left quadrant), cells at early stage of apoptosis, (upper left quadrant), cell at 
late stage of apoptosis (upper right quadrant), necrotic cells (lower right quadrant). Because of 
the high sensitiveness of this procedure, we detected higher levels of apoptosis as compared 
to that obtained at the analysis of subdiploid peak. Vp-16 at 17 mM increased the percentage 
of early and late apoptotic cells from 13 to 48% and decreased the percentage of viable cell 
from 75 to 49% (Figure 2A,D). Aspirin cotreatment at 2 and 5 mM dose-dependently 
decreased the percentage of early and apoptotic cells from 48 to 36 and 18%, respectively, 
(Figure 2D vs E,F) and increased the percentage of viable cells from 49 to 59 and 70% 
(Figure 2D vs E,F); similar data were obtained for Vp-16 at 8.5 mM (data not shown) and 
CPT 11at 10 mM (Figure 3). Not significant change in the levels of necrosis was observed. 
 
 
 
 
 
I also evaluated whether the effects of aspirin co-treatment on anticancer drug responsiveness 
were unique of Caco-2 cells or were obtainable in other colon cancer cells showing different 
Cox 
isoform expression profile. I selected the colon cancer cell line SW480 being Cox-1 positive, 
but Cox-2 negative (Smith et al, 2000). SW480 cells were co-treated with aspirin and 
topoisomerase 
inhibitors under the above mentioned experimental conditions.Aspirin co-treatment at 2 and 5 
mM decreased both CPT 11- and VP-16-induced apoptosis. The effect was dose-dependent 
and 
in the same range of magnitude of that obtained in Caco-2 cells (data not shown). 
Data from our laboratory indicated that Caco-2 cells express Cox-2 but not Cox-1 and NS-
398, a COX-2 selective inhibitor, inhibited DNA synthesis and induced apoptosis in Caco-2 
cells (Di Popolo et al, 2000). To evaluate whether the effects of aspirin co-treatment on Caco-
2 cells were dependent on the inhibition of Cox-2 activity, I analysed the effect of NS-398 co-
treatment on anticancer drug induced apoptosis. I firstly evaluated the effect on apoptosis of 
NS-398 72 h treatment at different concentration using annexin V-FITC/propidium iodide 
staining assay. As shown in Figure 4, 10 and 50 mM NS-398 treatment induced higher level 
of apoptosis compared with 2 and 5 mM aspirin treatments in Caco-2 cells (22 and 25% 
compared with 12 and 20%, respectively). 
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Then I evaluated the effect of NS-398 co-treatment on Vp-16- and CPT 11-induced toxicity. 
The percentage of cells in early plus late apoptosis vs viable cells induced by co-treatments 
with aspirin or NS-398 and Vp-16 or CPT 11 are given in Figure 3. 
Aspirin at 2 and 5 mM dose-dependently decreased both Vp16- and CPT 11-induced 
apoptosis and increased cell viability. NS 398 at 10 mM increased both 17 mM Vp-16- and 10 
mM CPT 11-induced apoptosis (P50.05 and P40.05, respectively), while NS 398 at 50 mM 
decreased 17 mM Vp-16- and 10 mM CPT 11-dependent apoptosis (P40.05 and P50.05, 
respectively). NS 398 at 10 mM did not significantly alter the percentage of viable cells 
following treatment with Vp-16- or CPT 11 co-treated cells, while NS 398 at 50 mM 
increased cell viability of Vp-16-treated cells from 40 to 52% (P50.05). No effects were 
obtained on anticancer drug induced-apoptosis with NS 398 at 1 mM (data not shown). I 
examined whether aspirin and NS-398 treatments had any distinct effect on cell cycle 
parameter under the same experimental conditions. The distribution of cells in the phases of 
the cell cycle is presented in Table 1. 
 
 
 
 Aspirin treatment was associated with a modest dose-dependent increase in the proportion of 
cells in the S phase, while NS-398 did not significantly alter cell cycle parameters with 
respect to control cells. I also asked whether the different effect of aspirin and NS-398 on 
survival could be determined by a selective interference with anticancer drug-induced cell 
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cycle arrest. In fact, Vp-16 arrests cells in the pre-mitotic phase of the cell cycle leading to 
accumulation of the cells in the late S or G2 phase (Fearnhead et al, 1994; Downes et al, 
1994); while CPT 11 causes S phase slowing (Shao et al, 1997; McDonald and Brown, 1998). 
Effect of Vp-16 and CPT 11 treated, Vp-16 and CPT 11 plus aspirin or plus NS-398 co-
treated cells under previously described experimental conditions are shown in Table 2.  
 
 
 
I found that Vp-16, from lowest concentration of drug tested, increased the distribution of 
Caco-2 cells at the G2 phase of the cell cycle. In particular, VP-16 at 8.5 mM and 17 mM 
treatments were able to trap 85 and 91% of Caco-2 cells in the G2 phase of cell cycle, 
respectively. Whereas CPT 11 at 10 and 15 mM treatments accumulated 70 and 85% of Caco-
2 cells in the S phase of cell cycle, respectively (Table 2 and data not shown). Aspirin and 
NS-398 co-treatment  
had different effect on anticancer drug induced cell cycle distribution: in cells that have been 
co-treated with Vp-16 at 17 mM, aspirin dose-dependently increased the percentage of Caco-
2 cells at G0 –G1 phase of cell cycle. NS-398 at 10 mM had no effect on Vp-16-induced 
accumulation at the G2 phase of cell cycle, while at 50 mM increased the percentage of cells 
at G0 –G1 phase from 9 to 15%. In cells that have been co-treated with aspirin and CPT 11 at 
10 mM there was an increase in the percentage of cells at G0 –G1 phase similar to that 
observed in Vp-16 co-treated cells. NS-398 only at 50 mM concentration increased the 
percentage of cells at G0 –G1 phase from 22 to 32% (Table 2). 
Several reports indicate that cancer cells after a genotoxic treatment can take hours to many 
days before dying (Vidair et al, 1996; Han et al, 1997). To better evaluate the cytoprotective 
effect of aspirin, also with respect to potential delayed toxicity of Vp-16, we measured overall 
cell viability by performing a plating efficiency assay following 8.5 mM and 17 mM 
etoposide treatments and cotreatments with either 2 or 5 mM aspirin (Figure 5A,B). All 
replated control Caco-2 cells started to divide after a lag period of 48h (Figure 5A); they 
entered into the exponential phase of cell growth at day 4, and reached the stationary phase at 
day 14 (data not shown). Etoposide treatments at both concentrations produced an 
approximately 0.7-fold decrease of the cell number at day 4 after replating; the fraction of 
surviving cells entered into the logarithmic phase of cell growth only at day 8. On the 
contrary, aspirin co-treated cells more efficiently replated and started the exponential phase of 
cell growth at day 6, 5 mM aspirin co-treated cells showing the best profile of cell growth. 
Thus, aspirin co-treated cells appeared to be more viable and less sensitive to anticancer 
delayed toxicity. Etoposide at 34 mM was such a toxic treatment that cell restarted to divide 
only at day 11; nevertheless, cells cotreated with aspirin and etoposide also at this 
concentration, continued to show an advantage in cell growth (data not shown). 
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The molecular  mechanisms  responsible  for the effect of aspirin on cell cycle and 
survival 
 
From previous studies I demonstrated that aspirin treatment at millimolar concentration 
significantly prevented apoptosis and G2/M phase of cell cycle accumulation induced by the 
topoisomerase inhibitors etoposide and irinotecan (Ricchi et al., 2002). These effects were 
observed both in Caco-2 cells and in SW 480 cells independently from their COX’s profile of 
expression, thus suggesting that aspirin acted through a COX-independent mechanism (Ricchi 
et al., 2002).In the second year of my PHD program I try to investigate  the molecular 
mechanisms Cox2 indipendent responsible for the effect of aspirin on cell cycle and 
survival.To valuate the molecular pathway by aspirin induced , I analyzed the citoprotection 
of aspirin on apoptosis by serum deprivation. The effect on apoptosis was first evaluated by 
analyzing the percentage of sub-G1 population at flow cytometry. Spontaneous apoptosis of 
Caco-2 cells at day 4 of culture in complete culture medium was in the average 6% (data not 
shown); the percentage of apoptotic cells was approximately 8, 20, and 30 after serum 
deprivation for 48, 96, and 168 h, respectively (Fig. 5).  
 
 
 
The effect of 2 and 5 mM aspirin treatment on serum withdrawal induced apoptosis was first 
evaluated through the analysis of the subdiploid DNA peak at flow cytometry. Aspirin 
inhibited apoptosis in a statistically significant manner ( p   0.05) at all time points tested 
compared with untreated cells (Fig.5A). Aspirin (2 mM) treatment caused a 60% reduction in 
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apoptosis compared with untreated cells with the maximal effect at 96 h of serum deprivation. 
The percentage of apoptosis increased up to 11% after treatment with 5 mM aspirin but was 
unmodified during the starvation time. Similar results were obtained when the percentage of 
apoptotic cells was evaluated by annexin staining (Fig. 5B); however, because of the high 
sensitiveness of this procedure, higher levels of apoptosis were observed in untreated cells 
compared with those obtained at the analysis of subdiploid peak (Fig.5A).We also analyzed in 
the same experimental conditions the distribution of cells in the phases of the cell cycle. We 
did not find any relevant modification in cell cycle distribution between starved Caco-2 cells 
and cells cultured in complete medium in the presence or absence of aspirin for 48 h (data not 
shown). On the contrary, prolonged serum deprivation caused a time-dependent decrease in 
the proportion of cells in the G1 phase of cell cycle and increase in the proportion of cells in 
the G2/M phase of cell cycle (Fig.6). 
 
 
 
 
 Aspirin (5 mM) treatment and to a lesser extent 2 mM aspirin treatment counteracted the G1 
decrease and G2/M increase in cell cycle distribution induced by prolonged serum starvation 
leading to a profile of cell cycle similar to that of cells cultured in serum for 168 h (Fig. 6, 
data point “in serum” versus 96- and 168-h serum withdrawal). Data from our laboratory 
indicated that Caco-2 cells expressed COX-2 but not COX-1 (Di Popolo et al., 2000). To 
evaluate whether the effects of aspirin treatment on Caco-2 cells cycle and survival were 
dependent on the inhibition of COX-2 activity, I analyzed the effect of NS-398 treatment, a 
COX-2-selective inhibitor, on survival during serum deprivation. To address this issue, cells 
were starved in the presence of 10  m NS-398, a concentration that completely inhibits the 
biosynthesis of prostaglandin E2 in Caco-2 cells. NS-398 treatment at this concentration did 
not cause any significant modifications on apoptosis and cell cycle parameters with respect to 
starved cells (data not shown). These results, therefore, suggested that aspirin interfered with 
apoptosis and cell cycle modification induced by serum withdrawal in Caco-2 cells in a COX-
independent manner. We have previously shown that an autocrine IGF-II/IGF-Ir pathway 
sustains cells proliferation and survival of Caco-2 colon cancer cells (Zarrilli et al., 1994, 
1996). In particular, we and others have demonstrated that the PI3-kinase pathway 
preferentially, with respect to the MAP kinase pathway, delivered  an antiapoptotic and 
proliferative signal in Caco-2 cells (Di Popolo et al., 2000; Gauthier et al., 2001). Thus, it was 
of interest to evaluate whether aspirin treatment had any effect on MAP kinase and PI3-kinase 
pathways during Caco-2 serum deprivation. 
To address these questions, I focused on the activation status of ERK1 and ERK2, two major 
components of the MAP kinases cascade, and of the AKT protein that is a downstream 
effector of the PI3-kinase. Lysates from cells serum deprived for 96 h in the presence or 
absence of 2 and 5 mM aspirin were probed for phosphorylated AKT at Ser 473 and 
phosporylated ERK1/2 kinases. To evaluate the PI3-kinase/ AKT-dependent pathway in 
serum cultured cells and to compare the effects of aspirin in both culture conditions, lysates of 
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cells cultured in complete medium and treated for 96 h with 2 and 5 mM aspirin were also 
collected. The bands were quantified and normalized to total AKT and ERK2 protein kinases, 
respectively. As shown in Fig.7, aspirin treatment dose dependently induced activation of 
AKT protein and ERK1/2 protein with respect to untreated cells. 
 
 The relative densitometric analysis showed 1.5- and 2.7-fold increase for AKT protein phos- 
phorylation status after aspirin treatment at 2 and 5 mM, respectively (Fig. 7A) and 2.7-fold 
increase for ERK1/2 protein phosphorylation status after aspirin treatment at 5 mM in serum-
deprived cells (Fig. 7B). On the other hand, serum deprivation slightly reduced the activation 
status of Akt with respect to serum-cultured cells (Fig. 7A), but aspirin treatment, although to 
a lesser extent than in serum withdrawal, still induced phosphorylation of Akt (Fig. 7A). 
To directly demonstrate the activation of PI3-kinase by aspirin treatment in serum-starved 
cells, we analyzed the PI3-kinase activity in the pTyr immunoprecipitate from 96-h serum-
deprived Caco-2 cells in the absence (control) or presence of 2 and 5 mM aspirin. As shown 
in Fig. 8aspirin treatment dose dependently increased the levels of three phosphate 
phosphatidylinositols. 
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Because the molecular effects of aspirin have been observed after prolonged exposure to drug, 
we asked whether these effects could be related to a direct activation of PI3- kinase by 
aspirin. To address this issue, we evaluated the effect on AKT and ERK phosphorylation 
status after aspirin acute stimulation. After 24 h of serum deprivation, Caco-2 cells were 
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treated with aspirin at 5 mM and cell lysates were collected after 5, 10, 15, and 30 min of drug 
addition. As shown in Fig.9, 5 mM aspirin treatment transiently inducedactivation of AKT 
and ERK1/2 proteins with respect to serum- deprived cells after 10 min of exposure. 
 
 
To further evaluate the relative involvement of ERK1/2 and PI3-kinase pathways in Caco-2 
cells survival, we analyzed also the effects, during serum deprivation, of PD98059 or 
LY294002 inhibitor treatments alone and in combination with 2 and 5 mM aspirin (Fig. 10, A 
and B; Table 1).  
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Treatment with the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 alone 
did not cause any relevant change in activation status of AKT protein, slightly decreased 
ERK1/2 phosphorylation, but reduced apoptosis with respect to control cells (Fig. 10 Table 
1). The aspirin induced activation of AKT persisted in the presence of PD98059 (Fig. 10 A) 
but  PD98059 did not counteract 5 mM aspirin-induced activation of ERK1/2 kinases (Fig. 10 
B), thus suggesting that ERK1/2 kinases were activated by aspirin independently from MAP 
kinases. On the contrary, the PI3- kinase inhibitor LY294002 alone reduced basal activation 
of AKT (Fig. 10A) and further increased apoptosis from 19 to 35% with respect to control 
cells (Table 3). Furthermore, LY294002 in cotreatment with aspirin completely reduced AKT 
activation (Fig. 10 A) and partially reduced ERK1/2 activation induced by aspirin (Fig. 10 B), 
whereas increased apoptosis levels up to 40 and 45% in the presence of aspirin at 2 and 5 
mM, respectively (Table 3). These data suggest that in Caco-2 cells ERK1/2 kinase pathway 
could be, at least in part, under PI3-kinase pathway control. Similar data were obtained in 
aspirin-treated cells for 168h (data not shown). Because treatments with aspirin, through the 
activation of AKT protein via PI3-kinase pathway stimulation, and with PD98059, by 
decreasing MAP kinase activity, both reduce apoptosis, the above-mentioned findings support 
the hypothesis that PI3-kinase inhibition and MAP kinase activation are involved in apoptotic 
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response to serum deprivation in Caco-2 cells. I have previously shown that in Caco-2 cells 
cotreated with aspirin and topoisomerase inhibitors, apoptosis and overall toxicity induced by 
topoisomerase inhibitors were reduced (Ricchi et al., 2002). To further correlate this 
cytoprotective effect of aspirin with the activation status of AKT, I assayed AKT activation 
status after 17  M Vp-16 and 5 mM aspirin cotreatment, an experimental condition where 
maximal effect on overall viability have been observed (Ricchi et al., 2002). As shown in Fig. 
11, phosphorylation status o  AKT protein was 2-fold increased both in cells treated with 5 
mM aspirin and cells cotreated with aspirin at 5 mM and Vp-16, compared with untreated 
cells, whereas phosphorylation status of AKT protein was unmodified after Vp-16 treatment 
compared with untreated cells. 
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Finally, in the search for substrates of Akt that could be relevant to the survival-promoting 
effects of Akt in Caco-2 cells, I also evaluated the effects of aspirin treatment on 
phosphorylation of (Ser 136) Bad in the same experimental system. No effects were detected 
on phosphorylation status of Bad at Ser 136 both after acute (5–30 min) and 96-h aspirin 
treatments (data not shown). On the contrary, according to our previous data (Ricchi et al., 
2002), I found that aspirin long-term treatment caused a dose-dependent increase in the bcl-2 
levels (data not shown). Together, these results strongly suggest that the aspirin cytoprotective 
effect resides in the ability to activate AKT protein and to deliver antiapoptotic signals in the 
presence of different apoptotic stimuli. As reported previously, treatment with aspirin dose 
dependently inhibited growth (Ricchi et al., 1997). Furthermore, aspirin (2–5 mM) did not 
significantly affect Caco-2 cells viability and counteracted G2/M phase transition induced by 
topoisomerase inhibitors (Ricchi et al., 2002). My data mentioned above on cell cycle further 
reinforced the idea that aspirin treatment could also regulate some of the proteins involved in 
control of cell cycle checkpoints. Furthermore, it was previously shown that p21Cip/WAF1, 
but not p27 levels, were elevated in terminal differentiated and nondividing Caco-2 cells 
(Evers et al., 1996; Gartel et al., 1996) and were almost undetectable in Caco-2 proliferating 
cells (Zarrilli et al., 1999). I therefore evaluated the effect of aspirin treatment on 
p21Cip/WAF1 expression. Because it has been reported that induction of p21Cip/WAF1 could 
be a downstream event of the activation of the AKT/PKB and ERK1/2 kinase pathways 
(Olson et al., 1998; Lawlor and Rotwein, 2000a,b), I also studied whether PD98059 or 
LY294002 treatment, alone or in combination with 2 and 5 mM aspirin for 96 h could modify 
p21Cip/WAF1 expression in Caco-2 serum-starved cells. 
 
 As shown in Fig.12, p21Cip/WAF1 levels increased by approximately 2-fold and 4-fold in 
cells treated with aspirin at 2 and 5 mM, compared with untreated cells. PD98059 alone, or in 
combination with 2 and 5 mM aspirin, increased p21Cip/WAF1 levels by 2.7-, 5-, and 4.4-
 20 
fold, respectively, compared with untreated cells. On the contrary, LY294002 alone did not 
affect basal level of p21Cip/WAF1, whereas in combination with aspirin completely 
suppressed the increase of p21Cip/WAF1 expression induced by aspirin. The above-
mentioned data therefore demonstrated that the induction of p21Cip/WAF1 in Caco-2 serum-
starved cells was a downstream event of the activation of the PI3-kinase survival pathway. 
Then, I examined whether these treatments had any impact on cell cycle parameters under the 
same experimental conditions. Table 4 shows the effect of PD98059 and LY294002, alone or 
in combination with aspirin, on cell cycle distribution of Caco-2 cells. PD98059 alone and in 
the presence of aspirin increased the percentage of cells in G1 and S phases and almost 
suppressed the percentage of cells in G2/M phase of cell cycle compared with control cells. 
Interestingly, LY294002 alone increased the percentage of cells in G1 phase and reduced the 
percentage of cells in G2/M phase compared with control cells; on the contrary, LY294002 in 
cotreatment with aspirin at 2 and 5 mM increased the percentage of cells in G2/M phase from 
7 to 15%( p 0.05) and from 4 to 32% ( p 0.02) with respect to aspirin-treated cells. 
 
 
 
 
The occurrence of this molecular mechanism and this effect of aspirin also in vivo 
system. 
 
In this study, I aimed to test the ability of aspirin to activate PI3K/AKT pathway in vitro and 
in vivo in methylcholanthrene induced fibrosarcoma cells (Meth A) transplanted into BALB/c 
nude mice. 
Meth A cells were exposed for 72 hours at different concentrations of VP-16 and aspirin 
alone and in combination.Aspirin was used at 1, 2, and 3 mmol/L and VP-16 was used at 34 
and 68 µmol/L. Apoptosis was evaluated through the analysis of cells positive for Annexin V 
staining at flow cytometry. Spontaneous apoptosis of Meth A cells in culture medium was in 
the average 10%. Treatment with aspirin up to 3 mmol/L concentration did not increase 
significantly apoptosis in Meth A cells with respect to basal level (Fig. 13, top).  
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The percentage of apoptosis increased upto 11% following treatment with 5 mmol/L aspirin 
(data not shown). Conversely, VP-16 at 34 and 68 µmol/L dose dependently increased 
apoptosis from 26% to 46% (Fig. 14, top). In addition, the levels of apoptosis were 
significantly reduced (P < 0.05) for each concentration of VP-16 when given in the presence 
of all concentration of aspirin compared with single-agent treatment; Meth A cells cotreated 
with aspirin at 3 mmol/L were particularly resistant to VP-16-induced apoptosis (P < 0.002). 
Similar results were obtained when levels of apoptosis were evaluated with propidium iodide 
staining analysis (data not shown). These results indicated that VP-16 was an active 
anticancer agent in Meth A cells and that aspirin treatment reduced the ability of the drug to 
induce apoptosis. To evaluate whether the effects of aspirin cotreatment on anticancer drug 
responsiveness were also obtainable toward others anticancer agents, we tested the effect of 
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aspirin treatment on cisplatin-induced apoptosis. Meth A cells were cotreated with aspirin at 
1, 2, and 3 mmol/L and cisplatin at 2, 5, 10, and 20 µmol/L under the above mentioned 
experimental conditions. Aspirin cotreatment dose-dependently reduced cisplatin-induced 
apoptosis for each concentration of cisplatin tested. The effect of aspirin on apoptosis was of 
the same range of magnitude of that observed in VP-16 and aspirin cotreated Meth A cells 
(data not shown). 
To evaluate whether the cytoprotective effects of aspirin treatment on Meth A cells were 
dependent on the inhibition of COXs activity, I analyzed the effect of VP-16 cotreatments 
with DFU, a COX-2selective inhibitor, and with indomethacin, a nonsteroidal 
antiinflammatory drug that shows a COX-1/COX-2 ratio called the inhibition of COX isoform 
similar to that of aspirin. I used two different concentration of indomethacin and DFU both at 
doses well recognized to inhibit COX-1 and/or COX-2. Neither indomethacin at 50 and 100 
mol/L nor DFU at 0.1 and 0.5 mol/L, respectively, reduced VP-16-induced apoptosis in Meth 
A cells (Fig. 13, bottom). These results, therefore, indicated that the cytoprotective action was 
unique to aspirin and was not shared by indomethacin. 
To show that aspirin-induced cytoprotective effect correlated with the activation of AKT in 
Meth A cells, I assayed AKT activation status following VP-16 treatment in the presence or 
absence of aspirin. Lysates from cells treated with 1, 2, and 3 mmol/L aspirin alone or in the 
presence of VP-16 at 34 Amol/L for 72hours were probed for phosphorylated AKT at Ser473. 
The bands were quantified and normalized to total AKT protein kinases, respectively. As 
shown in Fig. 14, aspirin treatment, but not VP-16 treatment, induced activation of AKT 
protein with respect to control cells. 
 
 
 The relative densitometric analysis showed 7.4-, 9.5-, and 6.9-fold increase for AKT protein 
phosphorylation status following aspirin treatment at 1, 2, and 3 mmol/L, respectively (Fig. 
14). Moreover, phosphorylation status of AKT protein were 2-, 3.5-, and 4.2-fold increased 
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also in cells cotreated with 1, 2, and 3 mmol/L aspirin andVP-16, respectively, compared with 
untreated cells.To further confirm the involvement of PI3K/AKTsurvival pathway, I 
evaluated the effect of the PI3K inhibitor LY294002 on the activation of AKT in aspirin 
treated and cotreated Meth A cells. The use of LY294002 suppressed the activation induced 
by aspirin, restoring the basal level of AKT activation status (data not shown). 
To investigate whether our in vitro finding occurred also in vivo, I evaluated the effect of 
aspirin and VP-16 treatments in nude mice injected i.p. with Meth A tumor cells. 
BALB/c mice average starting weight was 24.75 g. Because the rapid growth of Meth A 
tumor cells induced ascites in control group, weight gain was used to monitor tumor burden in 
the animals. Figure 15 shows the percentage of increase in body weight with respect to initial 
weight in control group; after 5 days, when Meth A cells induced visible ascites, and after 14 
days from the inoculum, an average 10% and 53% increase (38.2g mean weight; data not 
shown) in weight was reached, respectively (Fig. 15). 
 
 
 
Later, surviving animals reaching a size not compatible with normal life and suffering for the 
great ascites developed were killed for bioethical reasons. Treatments started after 5 days 
from inoculum; animals (six for each group) were treated i.p. with either aspirin (15 and 45 
mg/kg) and VP-16 (4 mg/kg) alone or in combination with aspirin (at the dose of 15, 30, and 
45 mg/ kg) or with vehicle (control group). In case of coadministration, to mimic 
experimental condition obtained in vitro, aspirin and VP-16 were simultaneously injected at 
different sides of peritoneum. 
During the first 7 days of treatment (days 1–7), when animal death was not yet observed, 
follow-up was based on the calculation of the percentage of increase in animal weight with 
respect to first day of treatment (Fig. 16); during the subsequent days (days 8–32), the effects 
of different treatments were evaluated recording animal survival and were displayed with 
Kaplan-Meier curves (Fig. 17).  
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Treatment with VP-16 completely arrested tumor growth and ascites generation, and the 
suppression of Meth A tumor cell growth was associated with an 2 % of reduction in body 
weight at days 5 to 7 (Fig. 16). After 8 days from VP-16 treatment, 33.3% of animals died for 
causes not directly linked with weight increase (bleeding ascites and cachexia). In other 50% 
of animals, after a variable lag time from treatment, Meth A cells resumed a growth rate 
comparable with control, and animals were harvested for bioethical reason when they reached 
an average weight of 35 g (data not shown). In remaining 16.6% of animals, no tumor growth 
was detected until 25 days of observation (Fig. 17) and they remained tumor free for a period 
of observation of 40 days after treatment (data not shown). Therefore, although VP-16 
treatment was not able to definitively cure almost all animals, tumor growth was arrested and 
mouse survival duration was significantly increased with respect to control (P < 0.001) for all 
the duration of follow-up. Aspirin treatment as single agent at 15 and 45 mg/kg had no effect 
on animal body weight and survival with respect to the control group (Figs. 16 and 17); no 
precocious mortality for gastric toxicity was observed in the aspirin-treated groups. The 
combination of aspirin at 45 mg/kg and VP-16 did not significantly inhibit xenograft ascitic 
growth and did not produce any effects on animal survival compared with VP-16-treated 
group (P < 0.001), displaying a trend similar to control group (Figs. 16 and 17). These data 
suggest that the highest dose of aspirin abolished the activity and the efficacy of VP-16 in 
tumor-bearing mice. 
The combination of aspirin at 30 mg/kg and VP-16 produced an increase in body weight of a 
lesser extent compared with that observed in control group. However, a more rapid increase in 
weight gain after 5 days of treatment was observed in cotreated animal when compared with 
animal treated with VP-16 alone (P < 0.002at day 7; Fig. 16). 
 
After this lag of time, a statistically significant difference in survival was observed between 
these two groups of animals (Fig. 17); in fact, in group of cotreated animals, 33% of the 
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animals died for causes not directly linked with weight increase, and after day 15 from 
treatment, no animal survived (Fig. 17). These results indicate that aspirin cotreatment at 30 
mg/kg attenuates the activity and the efficacy of VP-16 although at a lesser extent than 
cotreatment at 45 mg/kg. Finally, in animals treated with the combination of aspirin at 15 
mg/kg and VP-16, the body weight reduction was slightly minor (P < 0.02) compared with 
that observed in animal treated with VP-16 alone (Fig. 16). Similarly, a minimal but not 
statistically significant difference in survival probability was observed (Fig. 17). These results 
suggest that 15 mg/kg aspirin is able to reduce the activity but not the efficacy of VP-16-
based therapy. 
To analyze the molecular pathways associated with aspirin treatment in Meth A–bearing 
mice, one animal was harvested 4 hours after completing treatment and ascitic fluid 
containing tumor cells from previously considered experimental points was collected for 
biochemical evaluation. Consistently with our in vitro finding, treatment with aspirin at 15 
and 45 mg/kg alone determined a 3.8- and 6.5-fold increase in activation status of AKT 
compared with control group, respectively (Fig. 18). 
 
 
 In addition, aspirin cotreated groups showed higher levels of activation of AKT with respect 
to vehicle-treated group (Fig. 18). Between several downstream targets of AKT, GSK-3 
represents a convergence site of multiple signaling pathways involved in cell fate (Li et al. 
2000, Loberg et al. 2002). Phosphorylation at Ser21 (-isoform) or Ser9 (-isoform) of GSK-3h 
by AKT leads to inhibition of its activity and reduces apoptosis. Inactivation of GSK-3 by 
AKT may thus contribute to antiapoptotic effects of PI3K/AKT signaling (Loberg et al., 
2002). Therefore, I evaluated the effect of different treatments on activation status of GSK-3. 
As shown in Fig. 18B, phosphorylation status of GSK-3 in Ser9 was increased in aspirin-
treated mice. The effect was of lesser extent with respect to that observed for AKT 
phosphorylation and persisted, at 45 mg/kg aspirin treatment, also in the presence of VP-16. 
These results indicate that aspirin activates the AKT-dependent survival pathway leading to 
increased phosphorylation of GSK-3 at Ser9. 
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DISCUSSION 
 
Mounting evidence suggest that aspirin and other NSAID are able to interfere with mitogenic 
signalling causing arrest of cells in the G0/G1 phase of the cell cycle and, depending on the 
doses and the drug, to induce apoptosis as conventional cytotoxic drugs (Lu et al, 1995; Shiff 
et al, 1995, 1996; Piazza et al, 1995; Arber et al, 1997). 
For these properties NSAIDs have been sporadically employed in clinical cancer therapy; 
more frequently, they are utilised as analgesic, occasionally concurrently chemotherapy 
administration without a profound knowledge of the potential interaction with anticancer 
drugs and their efficacy. To date, very little information has been reported on this subject; a 
paper describes the first extensive screen of commercially available NSAIDs with anticancer 
drugs and discusses the potential clinical benefits of such combinations (Duffy et al, 1998). 
More recently, several studies have investigated the possibility of Cox-2 selective inhibitor-
mediated enhancement of chemotherapeutic drug toxicity (Soriano et al, 1999; Hida et al, 
2000). There are not reports comparing the effects of Cox-2 selective inhibition on 
responsiveness of colon cancer cells to chemotherapy with that obtained with aspirin, the 
most frequently used medicinal drug also for its anti-aggregating properties and in the clinical 
treatment of inflammatory diseases. In particular, the use of aspirin for analgesia and 
antipyresis (650 mg of oral administration, six times more on average than the anti-platelet 
dose) results in peak plasma concentration of 25 mg ml (which corresponds approximately to 
0.15 mM). On the other hand, the high dose of aspirin required for the treatment of arthritis (4 
– 6 g of oral administration) determines aspirin plasma level up to 300 mg ml, which 
corresponds to 2 mM (Insel, 2001). The main purpose of the first part of my  study is to 
evaluate if combined treatment in vitro would produce interactive effects that could be 
relevant in the clinical use. We have previously demonstrated that aspirin and NS-398 
treatments are both associated with the inhibition of proliferation and induction of apoptosis 
of Caco-2 cells (Ricchi et al, 1997; Di Popolo et al, 2000). Numerous studies suggest that any 
interference with mitogenic signalling and cell cycle cause a modification in the 
responsiveness to conventional cytotoxic drugs. In this study , I investigate whether aspirin 
and NS-398 interference with cell proliferation has any effect on Caco-2 cells responsiveness 
to the topoisomerase poisons irinotecan and etoposide, anticancer agents that specifically 
require DNA synthesis to exert their toxicity.The data reported herein demonstrate that aspirin 
and NS-398 act as anticancer agents in Caco-2 colon cancer cells with cytostatic properties 
and with different ability to induce apoptosis at high dosages. Also, I show that they 
differently modify anticancer responsiveness to chemotherapy of Caco-2 cells. I have 
evaluated this effect mainly towards the induction of apoptosis. In fact, there is emerging 
evidence that resistance to antitumour treatments relies on reduced sensitivity to apoptosis 
induction (Fisher, 1994; Nagata, 1997); in this regard, my results demonstrate that aspirin 
treatment is able to counteract the proapoptotic effect of anticancer drugs in vitro. Aspirin co-
treatment produces, at all concentrations investigated, a reduction of anticancer drug-induced 
apoptosis in Caco- 2 cells and, at 5 mM, a reduction of S/G2 phase cell cycle accumulation. 
I hypothesise that the effects of high doses of aspirin cotreatment on anticancer drug-induced 
toxicity could be mainly explained by the almost complete inhibition of DNA synthesis and 
G1 cell cycle arrest obtained at this dose of aspirin that have been shown also to alter cell 
cycle-related proteins (Law et al, 2000; Marra et al, 2000); the reduced ability of such 
anticancer drugs to induce apoptosis in quiescent cells have been already observed (Nitiss and 
Wang, 1996: Lin et al, 1998). Furthermore, it is a common observation that agents able to 
interfere with cell cycle usually prevent the action of drugs active in the next phase of cell 
cycle (Lin et al, 1998). 
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Moreover, I clearly demonstrate by PI- and annexin V-staining that the reduced levels of 
apoptosis obtained in aspirin co-treatments are associated with an increase in cell viability of 
Caco-2 cells; this effect is also evident by the analysis of plating efficiency in aspirin-Vp 16 
co-treated cells; thus, these data indicate that aspirin co-treatment interferes not only with 
apoptotic death but also with overall toxicity induced by these anticancer drugs. In this regard, 
aspirin and its metabolite sodium salicylate have been found to be protective against 
neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures 
(Grilli et al, 1996); thus, my data may represent a further evidence of aspirin cytoprotective 
property against a cellular damage. 
In addition, PI- and annexin V-staining assay indicated that the cytoptotective effect of aspirin 
co-treatment is present not only in Caco-2 cells but also in the Cox-2 negative, Cox-1 positive 
Sw 480 colon cancer cell line. These data may suggest that aspirin interferes with 
topoisomerase poison-induced toxicity through a Cox-independent mechanism. On the other 
hand, my data show that NS-398 co-treatment may alternatively reduce or increase anticancer 
drug induced apopotosis, depending on the concentration. These effects are less powerful 
compared with those observed in the presence of aspirin. 
NS-398 at 1mm concentration completely inhibits the biosynthesis of prostaglandin E2 in 
Caco-2 cells (Acquaviva et al, unpublished data) without affecting anticancer drug 
responsiveness; NS 398, at 10 mm concentration, causes minimal enhancement of anticancer 
drug-induced apoptosis without modifying cell cycle parameters. On the contrary, my data 
show that NS-398, at dose of 50 mM, is cytoprotective and counteracts anticancer drugs 
induced cell cycle perturbation. Based on these findings, I postulated that the described 
effects of increasing dose of NS-398, as in the case of aspirin, might be dependent on 
regulation of cell cycle regulatory protein (Hung et al, 2000) and not related on the inhibition 
of Cox-2 activity; these data could also reinforce the hypothesis of the concurrent presence of 
Cox-2-dependent and independent mechanisms of action in the antiproliferative effect of 
individual selective Cox-2 inhibitors (Grosch et al, 2001; Smith et al, 2000). 
The second aim of my study, was tried to better elucidate the molecular mechanisms that link 
the aspirin-dependent effect on cell cycle to the resistance to other apoptotic stimuli. I used 
serum deprivation-induced apoptosis in Caco-2 cells as a model system to evaluate aspirin 
interference with death/ survival pathways. My data show that in Caco-2 cells apoptosis 
induced by serum deprivation is a late event accompanied with increase in G2/M cell cycle 
phase. These findings are in agreement with those obtained in different experimental systems 
in which PI3-kinase activity was found to be required for growth factor-dependent survival 
and differentiation (Kennedy et al., 1997; Eves et al., 1998) and in which MAP kinase 
cascade was responsible for cell cycle progression (Aliaga et al., 1999; Abbott and Holt, 
1999). My data show that aspirin treatment in Caco-2 cells interferes with serum deprivation-
induced apoptosis through PI3-kinase and ERK kinase pathways. I also show that the effect of 
aspirin on survival is mediated through the activation of the PI3-kinase. In fact, aspirin 
treatment in the presence of the specific PI3-kinase inhibitor LY294002 is able to revert the 
effect of aspirin on Caco-2 cells survival being even more toxic than LY294002 alone. On the 
other hand, the inhibition of MEK activity by PD98059 alone or in cotreatment with aspirin 
does not have the same effect of LY294002 and maintain the cytoprotective effect of aspirin. 
Further studies are needed to clarify at molecular level the role of PI3-kinase pathway in the 
observed aspirin-dependent activation of ERK kinase. That aspirin treatment has a direct 
effect on PI3-kinase and ERK kinase pathways is demonstrated by my data showing a 
transient activation of these pathways by acute aspirin treatment. However, because the 
majority of my data are obtained with aspirin long-term treatment, I cannot exclude that 
aspirin might have also an indirect effect through the IGFII/IGF-Ir autocrine loop that sustains 
Caco-2 cells survival (Zarrilli et al., 1994, 1996). Therefore, further studies are needed also to 
elucidate at molecular levels the site(s) of aspirin interference with the IGFII/IGF-Ir-
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dependent PI3-kinase survival pathway and the mechanism(s) responsible for PI3-kinase 
activation. 
My data show that aspirin not only prevents apoptosis but also the increase in G2 cell cycle 
after Caco-2 cells serum deprivation and dose dependently induces p21Cip/WAF1 expression. 
Mounting evidence indicates that p21Cip/WAF1 is a downstream target of the PI3-
kinase/AKT pathway. In fact, it has been shown in muscle cells that IGFI/IGF-I receptor 
activation regulates survival and differentiation through the stimulation of PI3-kinase that in 
turn activates AKT, which stimulates the expression of p21Cip/WAF1 (Lawlor and Rotwein, 
2000a,b). 
However, although it has been shown that AKT stimulates p21Cip/WAF1 expression, other 
reports indicate that the activated AKT phosphorylates p21Cip/WAF1 to prevent 
p21Cip/WAF1 nuclear localization and the p21Cip/WAF1-dependent cell cycle arrest, as well 
as Mdm2, to prevent Mdm2 nuclear localization and Mdm2-dependent degradation of p53, 
thus determining cell cycle progression (Zhou et al., 2001a,b). The data presented herein 
indicate that aspirin activates a survival pathway that is responsible for the induction of 
p21Cip/WAF1 also in Caco-2 cells and that there is a strict correlation between p21Cip/WAF1 
expression and its inhibitory function toward cell cycle progression. In fact, as well as 
restoring apoptosis induced by serum deprivation, treatment with LY294002 in the presence 
of aspirin leads to p21Cip/ WAF1 suppression and G2/M accumulation. Thus, the aspirin 
dependent activation of AKT/PKB protein and the induction of p21Cip/WAF1expression 
provides a mechanism for its ability to prevent apoptosis and G2/M phase accumulation 
induced by prolonged serum deprivation and Etoposide treatment and indicates a novel tool 
by which aspirin may control cell cycle without resulting in a toxic treatment in Caco-2 cells. 
In accordance with our data, the activation of a similar pattern has been recently shown by Yu 
and collaborators, who demonstrated that the overexpression of the receptor tyrosine kinase 
p185ERbB2 increased p21Cip/WAF1 expression, conferred resistance to taxol-induced 
apoptosis, and prevented cell entrance to G2/M phase (Yu et al., 1998). On the other hand, we 
found also that inhibition of the MEK pathway led to induction of p21Cip/WAF1 expression 
and G2/M cell cycle phase reduction; similarly, the highest increase of G2/M phase was 
observed during 5 mM aspirin and LY294002 cotreatment in presence of activation of 
ERK1/2 kinases and p21Cip/WAF1 suppression. Although the mechanism by which PD98059 
treatment increases p21Cip/WAF1 level remains unclear, the above-mentioned data both 
confirme the protective effect of PD98059 against apoptotic stimuli (Cho et al., 2002; Cuda et 
al., 2002) and strongly suggest that the apoptotic response to serum deprivation in Caco-2 
cells involves also the activation of MAP kinase pathway and p21Cip/WAF1 suppression both 
responsible for G2/M accumulation. 
These finding are in agreement with other reports showing that p21Cip/WAF1 expression 
could play a role in enhancing cell survival (Cheng et al., 2000), protecting various cell types 
from apoptosis after anticancer drug treatment (Waldman et al., 1997). Further studies are 
needed to clarify the effect of aspirin treatment on p21Cip/WAF1 expression and its 
phosphorylation status on the control of cell cycle check points in Caco-2 cells and the 
mechanism by which the coordinated activity of PI3-kinase and MAP kinase pathways 
regulates its expression and the  survival signaling. I found previously the involvement of 
PI3K/AKT pathway in cytoprotective property of aspirin in cultured colon cancer Caco-2cells 
(19).To verify that aspirin is able to activate this pathway in other cancer cells and ,also in 
vivo, I used the fibrosarcoma Meth A cells as a system to evaluate aspirin interference with 
anticancer drug-induced apoptosis in vitro and in vivo. My data showed for the first time that 
the antiapoptotic effects of aspirin are not cell type specific and operated in vivo through the 
activation of PI3K/AKT pathway. My data showed that aspirin exposure, but not other COX-
2selective and nonselective inhibitors, prevented apoptosis induced by VP-16 and cisplatin in 
Meth A cells. The in vitro data were consistent with previous results showing that aspirin 
protected cells from apoptosis through activation of PI3K/AKT. Because the AKT protein is 
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the downstream effector of PI3K, further studies are needed to clarify at molecular levels the 
site(s) of aspirin interference with the PI3K survival pathway and the mechanism(s) 
responsible for PI3K activation. Preliminary data from our group indicate that aspirin is able 
to induce acetylation status of p85 regulative subunit of PI3K. It is possible to postulate that 
the structural change by acetylation increase the level of PIP3, as shown previously (19), and 
induce activation of PDK1 kinase. 
Furthermore, the in vitro data reinforce the evidence coming from our and other previous 
experiments (6, 18, 19, 24) that high doses of aspirin slightly affected or may increase basal 
level of apoptosis but were protective from apoptosis induced by external toxic stimuli. This 
at the molecular level confirms the aspirin pleiotropic activity and suggests that the aspirin 
interference with different survival/death pathways determines a global prosurvival promoting 
effect. 
One of the major purposes of this study was to evaluate whether combined treatment in vivo 
would produce effects that could be relevant in the clinical use.My data indicated that aspirin 
as single agent did not affect Meth A cell growth while provided evidence that aspirin 
administration reduced in vivo the activity and the efficacy of VP-16 treatment in Meth A–
bearing mice. My data indicated also that in vivo aspirin operated in a dose-response fashion 
to reduce the outcome of anticancer treatment. This trend was evident behind the lowest dose 
and indicated that coadministration of minimum 30 mg/kg aspirin was required to produce a 
significant effect on animal survival. 
Furthermore, aspirin-induced increase of animal body weight and decrease of survival strictly 
correlates with the activation of AKT. My results agree with previous data showing that AKT 
activation in vivo is a major factor in the resistance of tumor cells to apoptosis induced by 
chemotherapeutic drugs (29). 
In addition, my in vivo data indicated that aspirin inhibited the activity of GSK-3, a key factor 
not only for survival and chemoresistance (30) but also for the attenuation of the cellular 
action of insulin (31). Because it has been shown that high-dose aspirin could improve 
glucose metabolism in humans (16) and that GSK-3 activity inhibitors may therapeutically 
benefit in treating insulin resistance and type 2diabetes (32), the data of this report should 
encourage further evaluation of the in vivo mechanism for aspirin hypoglycemic effect. 
Although an expanding literature is showing the role of nonsteroidal anti-inflammatory drugs 
used alone or in combination with conventional anticancer drugs and their ability to alter 
toxicity profile of anticancer drugs (33, 34), the use of aspirin in combination with anticancer 
drugs has never been investigated in vivo. In this study, I used doses of aspirin in vitro and in 
vivo approximately corresponding to that required for the treatment of arthritis and rheumatic 
fever. In fact, the clinical treatment of inflammation requires 2 to 5 g aspirin oral 
administration, which determines aspirin plasma level up to 1 to 3 mmol/L (35). In my 
experiments, the antiapoptotic effect of aspirin was observed starting at dose at least 10 times 
higher than those used for antiplatelet therapy (75 mg/d). Therefore, our finding could be of 
relevance in the clinical condition where treatment schedules involving both cytotoxic agents 
and high doses of aspirin are required, suggesting that cotreatment with aspirin could limit the 
outcome of anticancer therapy. 
In conclusion, my data reinforce the emerging and wide observation coming from neuronal 
models (17) that aspirin operates also in vivo as cytoprotective agent. I also show that aspirin 
cytoprotective effect is mediated through the activation of AKT pathway. Because AKT 
pathway mediates survival against a wide variety apoptotic stimuli, it should be also verified 
the possible involvement of this pathway as mechanism by which aspirin exerts 
neuroprotection. 
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MATERIALS AND METHODS 
 
Cell growth and culture. Caco-2 cells were routinely grown in 100 mm plastic dishes at 
37°C in a humidified incubator 5% CO2-95% air atmosphere in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% foetal calf serum, glutamine (2 mM), penicillin 
(100 u ml71), and streptomycin (100 mg ml71) and buffered with N-2-
hydroxyethylpiperazine-N'-2-ethane sulphonic acid (HEPES) (20 mM). The culture medium 
was changed every other day. Confluence was reached 6 – 8 days. 
Etoposide and irinotecan were a gift from Bristol-Myers- Squibb (Rome, Italy) and Rhone 
Poulen, respectively; anticancer drugs were diluted in DMEM to prepare 500x concentrated 
solutions. Aspirin (Sigma, Milan, Italy) was dissolved in a 0.1 M Tris-HCl pH 7.8 solution. 
The solutions were buffered with Tris base to obtain the final pH equal to that of control 
DMEM medium and prepared every two weeks. Experiments were performed in the absence 
or in the presence of aspirin. In aspirin untreated cells (control) anticancer drugs were added 
for 48 h at day 4 of culture. In treated cells aspirin was added at day 3 of culture for 24 h. 
Anticancer drugs were added for 48 h in presence of aspirin or NS 398 (co-treatment) without 
changing media. LY294002 (Calbiochem, Darmstadt, Germany) was dissolved in dimethyl 
sulfoxide and prepared as a 16.2 mM stock solution and added at a final concentration of 50 
 M. PD98059 (Calbiochem) was dissolved in dimethyl sulfoxide and prepared as an 8 mM 
stock solution and added at final concentration of 40µM. 
The transplantable sarcoma Meth A cells were kindly provided from Dr. Pramod 
Srivastava.Original tumor cell lines were induced by a single s.c. injection of 0.1 mg 3-
methylcholantrene dissolved in 0.1 mL sesame oil. Meth A cells have a welldefined 
immunogenicity and typically produce either solid (20, 21). The cells were maintained by 
continuous propagation in the peritoneal cavity of BALB/c mice (6–7 weeks old). 
In addition, Meth A cells can routinely grown in 100-mm plastic dishes at 37°C in a 
humidified atmosphere of 5% CO2 in air in DMEM supplemented with 10% FCS, glutamine 
(2mmol/L), penicillin (100 units/mL), and streptomycin (100 Ag/mL) and buffered with 
HEPES (20 mmol/L). All experiments in vitro were done after one passage from peritoneal 
cavity. 
Indomethacin (Sigma, Milan, Italy) was dissolved in DMSO and prepared every week, 5,5-
Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl-2(5H)-furanone (DFU) was kindly 
provided by Merck Frosst (Kirkland, Quebec, Canada), dissolved in DMSO, and prepared as 
10 mmol/L stock solutio 
 
Cell cycle analysis and apoptosis detection.In order to define the cell cycle distribution and 
apoptosis rate, Caco-2cells  were trypsinised, pelletted, fixed and Propidium Iodide (PI) 
stained as previously described (Nicoletti et al, 1991). PI staining fluorescence of individual 
cells was analysed by using a FACS Calibur flow cytometer apparatus (Becton & Dickinson, 
Mountain View, CA, USA) and the MODFIT analysis software. For each sample, at least 20 
000 events were stored. Apoptosis/necrosis ratio was additionally evaluated by using annexin 
V-FITC/PI double staining technique. Briefly, trypsinized Caco-2 and Meth-A were collected, 
including floating apoptotic cells and the cells spontaneously detached during washing 
procedure, and annexin V-FITC and PI co-stained by using a detection kit from Medical & 
Biological Laboratories Co, Ltd, Naka-ku Nagoya Japan, according to the manufacturer’s 
instructions. Fluorescence analysis was performed by a flow cytometer apparatus (Becton & 
Dickinson, Mountain View, CA, USA) and the Cell Quest analysis software. For each sample, 
at least 30 000 events were stored. Quadrant settings were based on the negative control. Each 
experiment was repeated at least three times.  
 
Plating efficiency assay. To determine anticancer drug responsiveness of Caco-2 cells a 
plating efficiency assay was performed following drug removal. After each treatment, cells 
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were trypsinised, washed and seeded (15 000 cells 6 well) in triplicate in 24 multiwell cluster 
dishes and counted at days 1, 4, 6, 8 and 11 of culture. 
 
Western blot analysis. Mouse monoclonal antibody anti- Bcl-2, rabbit polyclonal anti-human 
p21Cip/WAF1 antibody, mouse monoclonal antibodies against phosphorylated ERK1/2, and 
rabbit polyclonal against total ERK2 protein were from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). (Ser 473) Phosphorylated AKT and total AKT, phosphorylated glycogen synthase 
kinase (GSK)-3α/β (Ser21/Ser9) and GSK-3β were detected by using rabbit polyclonal 
antibody and mouse monoclonal antibody, from Cell Signaling Technology Inc. (Beverly, 
MA).Lysates from adherent cells collected by scraping were centrifuged at 12 000 g for 15 
min at 4°C. The protein concentration in cell lysates was determined by Bio-Rad Protein 
Assay (Bio-Rad, Richmond CA, USA) and 70µg of total protein from each sample was 
analysed. Proteins were separated by a 12% SDS-polyacrylamide gel electrophoresis and 
transferred on nitrocellulose membrane (Hybond-ECL Nitrocellulose, Amsherman, Rainham, 
UK). Membranes were blocked in 5% non-fat dry milk, and after three washes, were 
incubated for 1 h at 4°C with 0.5 mg ml71 of mouse monoclonal primary antibody in PBS. 
After five washes, filters were 
incubated for 1 h at 4°C with horseradish peroxidase-conjugated anti-mouse secondary 
antibodies (Bio Rad) diluted 1 : 2000 in PBS, 0.1% Tween. The membranes were then 
washed and protein bands were detected by an enhanced chemiluminescence system 
(Amersham Pharmacia Biotech). Control for loading and transfer was obtained by probing 
with anti-a-tubulin (Sigma) at1 : 4000 dilution. For quantitation of immunoblots, relative 
intensities of bands were quantified by densitometry with a desk scanner (Pharmacia 
Discovery system) and RFLPrint software (PDI, New York, USA). Cells were washed in cold 
PBS and lysed for 10 min at 48C with 1 ml of lysis buffer (50 mM Tris, pH 7.4, 0.5% NP40, 
0.01% SDS) containing protease inhibitors. 
 
PI3-Kinase Assay. Cells lysates (300 µg) were immunoprecipitated with a pTyr antibody 
(Santa Cruz Biotechnology, Inc.). Pellets were washed in cold PBS and then in 100 mM Tris-
HCl, pH 7.4, supplemented with 500 mM LiCl, 1 mM EDTA, and 0.2 mM NaVO4. 
Pellets were further resuspended in 30mMHEPES, pH 7.5, and 6.25mM MgCl2 and 125  M 
cold ATP; the kinase reaction was initiated by addition of 2  g/ l phosphatidylinositol (Sigma) 
and 10  Ci/ l [32P]ATP (3000 Ci/mmol) and performed for 15 min at 37°; the reaction was 
stopped by addition of 5 M HCl and 0.5 M EDTA and methanol/chloroform (1:1). After 
mixing vigorously and centrifuging to separate the phases, the organic layer was collected and 
separated by thin layer chromatography (TLC). [32P]phosphoinositides were visualized by 
autoradiographs, scraped from TLC, and counts per minute were quantified by a  -counter 
(Beckman Coulter, Inc., Fullerton,CA). 
 
Statistical Analysis. Statistical comparisons were performed using the Mann-Whitney U test. 
A probability value  0.05 was considered a significant difference. 
 
In vivo Studies. Female BALB/c mice (6–7 weeks old) were purchased from Charles River 
Laboratories (Milan, Italy). The research protocol was approved and mice were maintained in 
accordance to institutional guidelines of the University of Naples Animal Care and Use 
Committee. Mice were acclimatized at the University of Naples Medical School Animal 
Facility for 1 week before injection with cancer cells. All these animals received 1 million 
Meth A tumor cells in 0.2mL saline on day 0. VP-16 was used at 4 mg/kg, and aspirin was 
used at 15,30, and 45 mg/kg. After 5 days, when established ascites were evident and animal 
weight started to increase, seven mice per group were treated i.p. at the indicated doses of 
aspirin alone or in combination with VP-16. Drugs were given (on days 1–3) for 3 days every 
2 4hours. Control group was injected with vehicle. All animals were injected i.p. with an 
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equal volume of solvent as a control (300 AL). Then, mice were randomly divided into seven 
groups [1 control group, 1 VP-16-treated group, 2aspirin-treated groups (15 and 45 mg/kg), 
and 3 aspirin and VP-16 cotreated groups], with each group containing seven animals. Of 
each group, six animals were observed daily to monitor their survival and their weight 
increase and one animal was killed 4 hours after completing treatment; ascitic fluid containing 
tumor cells was collected in PBS with proteases and phosphatases inhibitors and processed as 
described in Western Blot Analysis. 
Statistical Analysis. Statistical comparisons were done using the Mann-Whitney U test and 
log-rank test. P < 0.05 was considered a significant difference. 
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